

REMARKS

The specification has been amended in order to update the cross-reference to related application information and to amend the Abstract.

Claims 1, 5, and 16 are cancelled. Claim 1 is replaced by new claim 17. Claims 5 and 16 are redundant in view of new claim 19 and the subject matter allowed in parent application Serial No. 09/125,168.

Claims 2-4, 6, and 9-15 are amended to put them in appropriate U.S. claim format and to eliminate multiple dependencies.


New claims 17-19 are added. Claim 17 corresponds to original claim 15 as well as original claim 1 written in U.S. method-of-use format. Support for claims 18 and 19 are found, for example, in original claims 15 and 16.

No new matter is introduced by the present amendments.

Claims 2-4, 6-15, and 17-19 are in the application as amended.

Respectfully submitted,

Dated: 3/26/04


PAUL E. DUPONT
Registration No. 27,438

Sanofi-Synthelabo Inc.
9 Great Valley Parkway
Malvern, PA 19355
Tel.: (610) 889-6338
Fax: (610) 889-8799